Prestige Consumer Healthcare Inc (PBH)
72.60
-0.03
(-0.04%)
USD |
NYSE |
Mar 28, 16:00
72.60
0.00 (0.00%)
After-Hours: 17:05
Prestige Consumer Healthcare SG&A Expense (Quarterly): 65.47M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 65.47M |
September 30, 2023 | 66.10M |
June 30, 2023 | 63.92M |
March 31, 2023 | 58.53M |
December 31, 2022 | 56.96M |
September 30, 2022 | 70.26M |
June 30, 2022 | 66.66M |
March 31, 2022 | 63.69M |
December 31, 2021 | 66.22M |
September 30, 2021 | 72.98M |
June 30, 2021 | 61.91M |
March 31, 2021 | 57.81M |
December 31, 2020 | 59.48M |
September 30, 2020 | 58.73M |
June 30, 2020 | 47.68M |
March 31, 2020 | 63.75M |
December 31, 2019 | 54.87M |
September 30, 2019 | 61.18M |
June 30, 2019 | 56.51M |
March 31, 2019 | 285.19M |
December 31, 2018 | 54.99M |
September 30, 2018 | 61.08M |
June 30, 2018 | 61.05M |
March 31, 2018 | 57.48M |
December 31, 2017 | 56.66M |
Date | Value |
---|---|
September 30, 2017 | 61.19M |
June 30, 2017 | 57.35M |
March 31, 2017 | 70.18M |
December 31, 2016 | 52.81M |
September 30, 2016 | 47.39M |
June 30, 2016 | 47.09M |
March 31, 2016 | 46.78M |
December 31, 2015 | 48.07M |
September 30, 2015 | 44.36M |
June 30, 2015 | 44.01M |
March 31, 2015 | 43.05M |
December 31, 2014 | 49.60M |
September 30, 2014 | 52.17M |
June 30, 2014 | 36.10M |
March 31, 2014 | 30.60M |
December 31, 2013 | 36.37M |
September 30, 2013 | 36.17M |
June 30, 2013 | 30.32M |
March 31, 2013 | 31.13M |
December 31, 2012 | 34.92M |
September 30, 2012 | 36.09M |
June 30, 2012 | 36.48M |
March 31, 2012 | 42.88M |
December 31, 2011 | 28.93M |
September 30, 2011 | 21.93M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
47.68M
Minimum
Jun 2020
285.19M
Maximum
Mar 2019
72.89M
Average
62.80M
Median
SG&A Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 2.943M |
Palatin Technologies Inc | 3.033M |
iBio Inc | 2.961M |
Theriva Biologics Inc | 0.212M |
Ampio Pharmaceuticals Inc | 1.071M |